These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

527 related items for PubMed ID: 8391792

  • 1. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis.
    Simonneau G, Charbonnier B, Decousus H, Planchon B, Ninet J, Sie P, Silsiguen M, Combe S.
    Arch Intern Med; 1993 Jul 12; 153(13):1541-6. PubMed ID: 8391792
    [Abstract] [Full Text] [Related]

  • 2. An open-label, comparative study of the efficacy and safety of once-daily dose of enoxaparin versus unfractionated heparin in the treatment of proximal lower limb deep-vein thrombosis.
    Ramacciotti E, Araújo GR, Lastoria S, Maffei FH, Karaoglan de Moura L, Michaelis W, Sandri JL, Dietrich-Neto F, CLETRAT Investigators.
    Thromb Res; 2004 Jul 12; 114(3):149-53. PubMed ID: 15342210
    [Abstract] [Full Text] [Related]

  • 3. Dosage, anticoagulant, and antithrombotic effects of heparin and low-molecular-weight heparin in the treatment of deep vein thrombosis.
    Harenberg J, Stehle G, Blauth M, Huck K, Mall K, Heene DL.
    Semin Thromb Hemost; 1997 Jul 12; 23(1):83-90. PubMed ID: 9156415
    [Abstract] [Full Text] [Related]

  • 4. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial.
    Lopaciuk S, Meissner AJ, Filipecki S, Zawilska K, Sowier J, Ciesielski L, Bielawiec M, Glowinski S, Czestochowska E.
    Thromb Haemost; 1992 Jul 06; 68(1):14-8. PubMed ID: 1325076
    [Abstract] [Full Text] [Related]

  • 5. A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group.
    Bergmann JF, Neuhart E.
    Thromb Haemost; 1996 Oct 06; 76(4):529-34. PubMed ID: 8902991
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
    Holzheimer RG.
    Eur J Med Res; 2004 Apr 30; 9(4):225-39. PubMed ID: 15210403
    [Abstract] [Full Text] [Related]

  • 11. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
    Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, Ginsberg J, Turpie AG, Demers C, Kovacs M.
    N Engl J Med; 1996 Mar 14; 334(11):677-81. PubMed ID: 8594425
    [Abstract] [Full Text] [Related]

  • 12. Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism.
    Prandoni P, Carnovali M, Marchiori A, Galilei Investigators.
    Arch Intern Med; 2004 May 24; 164(10):1077-83. PubMed ID: 15159264
    [Abstract] [Full Text] [Related]

  • 13. Reduction in thrombus extension and clinical end points in patients after initial treatment for deep vein thrombosis with the fixed-dose body weight-independent low molecular weight heparin certoparin.
    Harenberg J, Huisman MV, Tolle AR, Breddin HK, Kirchmaier CM.
    Semin Thromb Hemost; 2001 Oct 24; 27(5):513-8. PubMed ID: 11668421
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial.
    Stellbrink C, Nixdorff U, Hofmann T, Lehmacher W, Daniel WG, Hanrath P, Geller C, Mügge A, Sehnert W, Schmidt-Lucke C, Schmidt-Lucke JA, ACE (Anticoagulation in Cardioversion using Enoxaparin) Study Group.
    Circulation; 2004 Mar 02; 109(8):997-1003. PubMed ID: 14967716
    [Abstract] [Full Text] [Related]

  • 19. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
    Kakkar VV, Howes J, Sharma V, Kadziola Z.
    Thromb Haemost; 2000 Apr 02; 83(4):523-9. PubMed ID: 10780310
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.